Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbro Linderholm

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 14, 2017
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramShusma C Doebar, Leen Slaets, Fatima Cardoso, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohortLuca Visani, Ivica Ratosa, Rupert Bartsch, et al.
NPJ Breast Cancer|December 20, 2025
Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastasesKatarzyna J Jerzak, Evangelia D Razis, Elisa Agostinetto, et al.
The Oncologist|June 13, 2023
Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG)Carolien P Schröder, Elise van Leeuwen-Stok, Fatima Cardoso, et al.
BMJ Open|August 27, 2025
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNEAlexios Matikas, Bjørn Naume, Hans Wildiers, et al.
Breast (Edinburgh, Scotland)|June 17, 2026
De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world studyTal Sella, Frederieke van Duijnhoven, Hans Wildiers, et al.
Breast (Edinburgh, Scotland)|December 12, 2025
Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapyAyelet Shai, Hans Wildiers, Claudio Venieri, et al.
NPJ Breast Cancer|July 27, 2021
Evaluation of multiple transcriptomic gene risk signatures in male breast cancerJane Bayani, Coralie Poncet, Cheryl Crozier, et al.
JAMA|April 2, 2024
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerRoberto A Leon-Ferre, Sarah Flora Jonas, Roberto Salgado, et al.
The New England Journal of Medicine|June 3, 2021
Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast CancerAndrew N J Tutt, Judy E Garber, Bella Kaufman, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 14, 2017
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramShusma C Doebar, Leen Slaets, Fatima Cardoso, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohortLuca Visani, Ivica Ratosa, Rupert Bartsch, et al.
NPJ Breast Cancer|December 20, 2025
Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastasesKatarzyna J Jerzak, Evangelia D Razis, Elisa Agostinetto, et al.
The Oncologist|June 13, 2023
Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG)Carolien P Schröder, Elise van Leeuwen-Stok, Fatima Cardoso, et al.
BMJ Open|August 27, 2025
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNEAlexios Matikas, Bjørn Naume, Hans Wildiers, et al.
Breast (Edinburgh, Scotland)|June 17, 2026
De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world studyTal Sella, Frederieke van Duijnhoven, Hans Wildiers, et al.
Breast (Edinburgh, Scotland)|December 12, 2025
Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapyAyelet Shai, Hans Wildiers, Claudio Venieri, et al.
NPJ Breast Cancer|July 27, 2021
Evaluation of multiple transcriptomic gene risk signatures in male breast cancerJane Bayani, Coralie Poncet, Cheryl Crozier, et al.
JAMA|April 2, 2024
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerRoberto A Leon-Ferre, Sarah Flora Jonas, Roberto Salgado, et al.
The New England Journal of Medicine|June 3, 2021
Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast CancerAndrew N J Tutt, Judy E Garber, Bella Kaufman, et al.
Pageof 5